Radiopharm Theranostics (RADX) Cash & Equivalents (2024 - 2025)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Radiopharm Theranostics (RADX) has disclosed Cash & Equivalents for 2 consecutive years, with $29.1 million as the latest value for Q2 2025.

• Quarterly Cash & Equivalents rose 56.75% to $29.1 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $29.1 million through Jun 2025, up 56.75% year-over-year, with the annual reading at $29.1 million for FY2025, 56.75% up from the prior year.
• Cash & Equivalents for Q2 2025 was $29.1 million at Radiopharm Theranostics, up from $18.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $29.1 million in Q2 2025, with the low at $18.6 million in Q2 2024.

Peer Comparison